Cargando…

Treatment with Natalizumab in Relapsing–Remitting Multiple Sclerosis Patients Induces Changes in Inflammatory Mechanism

Natalizumab is a widely accepted drug for the relapsing–remitting subtype of multiple sclerosis (RRMS). The present longitudinal exploratory study in RRMS patients analyzes the effects of natalizumab treatment on the levels of pro-inflammatory and anti-inflammatory cytokine protein levels and also t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ramos-Cejudo, Jaime, Oreja-Guevara, Celia, Stark Aroeira, Luiz, Rodriguez de Antonio, Luis, Chamorro, Beatriz, Diez-Tejedor, Exuperio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2011
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3155864/ https://www.ncbi.nlm.nih.gov/pubmed/21491095 http://dx.doi.org/10.1007/s10875-011-9522-x

Ejemplares similares

TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab
por: Oreja-Guevara, Celia, et al.
Publicado: (2012)

Clinically Isolated Syndromes Suggestive of Multiple Sclerosis: An Optical Coherence Tomography Study
por: Oreja-Guevara, Celia, et al.
Publicado: (2012)

Natalizumab: A new treatment for relapsing remitting multiple sclerosis
por: Hutchinson, Michael
Publicado: (2007)

Natalizumab is Effective for the Treatment of Relapsing-remitting Tumefactive Multiple Sclerosis
por: Nakamura, Masataka, et al.
Publicado: (2017)

Use of Natalizumab in Patients with Active Relapsing-Remitting Multiple Sclerosis in Kuwait
por: Alroughani, R., et al.
Publicado: (2013)

A randomized study of natalizumab dosing regimens for relapsing–remitting multiple sclerosis
por: Trojano, Maria, et al.
Publicado: (2021)

Bruising following natalizumab infusion for relapsing-remitting multiple sclerosis: a case report
por: Gatzonis, Stylianos, et al.
Publicado: (2009)

Impact of Natalizumab on Ambulatory Improvement in Secondary Progressive and Disabled Relapsing-Remitting Multiple Sclerosis
por: Cadavid, Diego, et al.
Publicado: (2013)

Impact of Natalizumab Treatment on Fatigue, Mood, and Aspects of Cognition in Relapsing–Remitting Multiple Sclerosis
por: Kunkel, Annett, et al.
Publicado: (2015)

Extended Interval Dosing Natalizumab and impact on neuropsychological deficits in Relapsing-Remitting Multiple Sclerosis
por: McManus, Eileen J., et al.
Publicado: (2022)

Cost-effectiveness analysis of rituximab versus natalizumab in patients with relapsing remitting multiple sclerosis
por: Rezaee, Mehdi, et al.
Publicado: (2022)

Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients
por: van Lierop, ZYGJ, et al.
Publicado: (2021)

Antibody Content against Epstein–Barr Virus in Blood Extracellular Vesicles Correlates with Disease Activity and Brain Volume in Patients with Relapsing–Remitting Multiple Sclerosis
por: Fernández-Fournier, Mireya, et al.
Publicado: (2023)

Long-term safety and efficacy of natalizumab in relapsing-remitting multiple sclerosis: impact on quality of life
por: Planas, Raquel, et al.
Publicado: (2014)

Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
por: Grahl, S., et al.
Publicado: (2021)

Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
por: Perumal, Jai, et al.
Publicado: (2021)

Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom
por: Spelman, Timothy, et al.
Publicado: (2021)

Treatment with natalizumab during the Covid-19 pandemic in multiple sclerosis patients
por: Díaz-Díaz, Judit, et al.
Publicado: (2021)

Cost-effectiveness analysis of escalating to natalizumab or switching among immunomodulators in relapsing-remitting multiple sclerosis in Italy
por: Furneri, Gianluca, et al.
Publicado: (2019)

Correction to: Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
por: Perumal, Jai, et al.
Publicado: (2021)

Effect of Rituximab Compared with Natalizumab and Fingolimod in Patients with Relapsing–Remitting Multiple Sclerosis: A Cohort Study
por: Hernández-Preciado, Martha Rocio, et al.
Publicado: (2022)

Clinical and economic evaluations of natalizumab, rituximab, and ocrelizumab for the management of relapsing-remitting multiple sclerosis in Saudi Arabia
por: Alharbi, Mansour A., et al.
Publicado: (2023)

Remitting–relapsing multiple sclerosis patient refractory to conventional treatments and bone marrow transplantation who responded to natalizumab
por: Mouzaki, Athanasia, et al.
Publicado: (2010)

Identification of CD4(+) T cell biomarkers for predicting the response of patients with relapsing-remitting multiple sclerosis to natalizumab treatment
por: Fagone, Paolo, et al.
Publicado: (2019)

Long-term effects of natalizumab on MRI activity and clinical outcomes in Japanese patients with relapsing-remitting multiple sclerosis
por: Saida, Takahiko, et al.
Publicado: (2023)

Serum glial fibrillary acidic protein in natalizumab-treated relapsing-remitting multiple sclerosis: An alternative to neurofilament light
por: Wessels, Mark HJ, et al.
Publicado: (2023)

Natalizumab Treatment of Relapsing Remitting Multiple Sclerosis Has No Long-Term Effects on the Proportion of Circulating Regulatory T Cells
por: Tanasescu, Radu, et al.
Publicado: (2023)

Natalizumab for the treatment of relapsing multiple sclerosis
por: Rudick, Richard A, et al.
Publicado: (2008)

Natalizumab treatment of multiple sclerosis in Spain: results of an extensive observational study
por: Fernández, O., et al.
Publicado: (2012)

Rapid Progression of Low-Grade Cervical Dysplasia into Invasive Cancer during Natalizumab Treatment for Relapsing Remitting Multiple Sclerosis
por: Wan, King Man, et al.
Publicado: (2019)

Modified Rio Score with Platform Therapy Predicts Treatment Success with Fingolimod and Natalizumab in Relapsing-Remitting Multiple Sclerosis Patients
por: Jamroz-Wiśniewska, Anna, et al.
Publicado: (2021)

Neurofilament-light and contactin-1 association with long-term brain atrophy in natalizumab-treated relapsing-remitting multiple sclerosis
por: van Lierop, Zoë YGJ, et al.
Publicado: (2022)

Spanish real-world experience with fingolimod in relapsing-remitting multiple sclerosis patients: MS NEXT study
por: Barrero, Francisco, et al.
Publicado: (2020)

Unraveling Natalizumab Effects on Deregulated miR-17 Expression in CD4(+) T Cells of Patients with Relapsing-Remitting Multiple Sclerosis
por: Meira, Maria, et al.
Publicado: (2014)

Natalizumab improves ambulation in relapsing−remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM
por: Voloshyna, N, et al.
Publicado: (2015)

Long-term evaluation of NEDA-3 status in relapsing-remitting multiple sclerosis patients after switching from natalizumab to fingolimod
por: Diem, Lara, et al.
Publicado: (2018)

No increase of serum neurofilament light in relapsing-remitting multiple sclerosis patients switching from standard to extended-interval dosing of natalizumab
por: Johnsson, Magnus, et al.
Publicado: (2022)

Comparative efficacy of switching to natalizumab in active multiple sclerosis
por: Spelman, Timothy, et al.
Publicado: (2015)

Is natalizumab a safe treatment for patients with multiple sclerosis in the COVID-19 pandemic? Data from the first year of the pandemic
por: Díaz-Díaz, Judit, et al.
Publicado: (2021)

Safety and Efficacy of Natalizumab in Japanese Patients with Relapsing-Remitting Multiple Sclerosis: Open-Label Extension Study of a Phase 2 Trial
por: Saida, Takahiko, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_t1ms632fn4u1kmcovlagvd4p0s